Skip to main navigation
DURECT
  • ABOUT
    • ABOUT DURECT
    • MANAGEMENT
    • BOARD OF DIRECTORS
    • CORPORATE GOVERNANCE
      • BOARD COMMITTEE CHARTERS
      • CODE OF ETHICS
      • WHISTLEBLOWER POLICY
      • CORPORATE GOVERNANCE GUIDELINES
  • DUR-928
    • OVERVIEW
    • EPIGENETIC REGULATION
    • ALCOHOLIC HEPATITIS
    • COVID-19
    • NONALCOHOLIC STEATOHEPATITIS (NASH)
    • PUBLICATIONS
    • EXPANDED ACCESS POLICY
  • PIPELINE
    • OVERVIEW
    • IN DEVELOPMENT
      • DUR-928
      • POSIMIR (bupivacaine extended-release solution)
      • ORADUR® -Methylphenidate ER
      • Investigational Long-acting HIV Product
  • PLATFORM TECHNOLOGIES
    • LONG-ACTING INJECTABLES
      • SABER® PLATFORM
      • CLOUD™ PLATFORM
    • ORADUR™ ABUSE-DETERRENT TECHNOLOGY
    • ALZET® Osmotic Pumps
  • INVESTORS

    Investor Relations

    • Overview
    • FACTSHEETS
    • Stock Information
    • News Releases
    • Collaborations
    • Earnings Estimate
    • Analyst Coverage
    • Corporate Presentation
    • SEC Filings
    • Event Calendar
    • FAQs
    • E-mail Alerts
    • Information Request
  • NEWS
    • NEWS RELEASES
    • MEDIA KIT

INVESTORS

Investor Relations

  • Overview
  • FACTSHEETS
  • Stock Information
  • News Releases
  • Collaborations
  • Earnings Estimate
  • Analyst Coverage
  • Corporate Presentation
  • SEC Filings
  • Event Calendar
  • FAQs
  • E-mail Alerts
  • Information Request

News Releases

 

This information is part of the archives and is no longer current and may no longer be accurate.

Keyword Search

Date Title
Jan 05, 2021
 DURECT Corporation Appoints Two New Board Members
Jan 04, 2021
 DURECT Corporation Announces Closing of LACTEL® Absorbable Polymer Product Line Sale to Evonik and Receipt of $15 Million

© 2000-2021 DURECT Corporation

BUSINESS DEVELOPMENT | CAREERS | CONTACT | LEGAL NOTICE | PRIVACY POLICY